– Hematopoietic Stem cell mobilization by Using Ara-C – NK activity in Hematologic malignancies – Distribution of NK cell and MSC after Intravenous infusion – Prevention of mucositis in HSCT patients – Belantamab mafadotin in Relapsed/Refractory MM – Tafasitamab in Relapsed/Refractory DLBCL – Mosunetuzumab in Relapsed/Refractory DLBCL – Odronextamab in Relapsed/Refractory DLBCL – CAR T-cell therapy in Double hit or double expressor DLBCL – CAR T-cell therapy in Relapsed/Refractory B-ALL